All In Biotech

Drug Trial Radar · NCT03795974

Efficacy of Allogeneic Umbilical Cord Derived Hematopoietic and Mesenchymal Stem Cells in Cerebral Palsy

Evaluation of the Efficacy of Allogeneic Umbilical Cord Derived Hematopoietic Stem Cells and Mesenchymal Stromal Cells in Patients With Spastic Cerebral Palsy on Developmental Function , A Clinical Trial phase2

Last checked: Nov 20, 2026Latest source record: Jan 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

108

Actual

Start

Jul 23, 2017

Primary completion

Oct 2019

Study completion Dec 2019

Sponsor

Lead sponsor
Tehran University of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hormozgan University of Medical Sciences
First posted
Jan 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 4 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cerebral palsy(CP) consisted of a group of developmental disability in the field of motor function and is one of the major problems of pediatric neurology and at the present time there is no standard curative medical or surgical treatment for it .Stem cell therapy is one of a new and hopeful therapeutic methods of therapy for CP .This double blind study designed for the evaluation of safety and therapeutic effects of intrathecal hematopoietic and mesenchymal stem cells derived from allogenic umbilical cord in change and probable improvement of developmental functions of spastic CP participants between 4-14 years old and comparing with control group of CP participants without cell therapy . 108 cases recruited and randomly divided to 3 groups of 36 cases : hematopoietic stem cells derived from allogenic umbilical cord , Mesenchymal cells derived from allogenic umbilical cord and control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators . Developmental functions and spasticity evaluated before intervention and will be done 1 , 3 , 6 and 12 months after injection . During this period neuro rehabilitation will be continued . Brain neuroimaging were done at the recruitment time and will be repeated after 12 months .

Conditions

  • Cerebral Palsy, Spastic

Interventions

  • MNCBiological

    Hematopoietic stem cells derived from allogenic umbilical cord

  • MSCBiological

    Mesenchymal cells derived from allogenic umbilical cord

  • ControlProcedure

    control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators , but rehabilitation continued .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline Gross Motor Function Classification System (GMFCS)Time frame: Baseline
  2. Change from baseline Gross Motor Function Classification System (GMFCS)Time frame: "month" 3
  3. Change from baseline Gross Motor Function Classification System (GMFCS)Time frame: "month" 6
  4. Change from baseline Gross Motor Function Classification System (GMFCS)Time frame: "month" 12
  5. Change from baseline GROSS MOTOR FUNCTION MEASURE (GMFM66)Time frame: Baseline
  6. Change from baseline GROSS MOTOR FUNCTION MEASURE (GMFM66)Time frame: "month" 1
  7. Change from baseline GROSS MOTOR FUNCTION MEASURE (GMFM66)Time frame: "month" 3
  8. Change from baseline GROSS MOTOR FUNCTION MEASURE (GMFM66)Time frame: "month" 6
  9. Change from baseline GROSS MOTOR FUNCTION MEASURE (GMFM66)Time frame: "month" 12
  10. Change from baseline Manual Ability Classification System for Children with Cerebral Palsy (MACS)Time frame: Baseline
  11. Change from baseline Manual Ability Classification System for Children with Cerebral Palsy (MACS)Time frame: "month" 3
  12. Change from baseline Manual Ability Classification System for Children with Cerebral Palsy (MACS)Time frame: "month" 6
  13. Change from baseline Manual Ability Classification System for Children with Cerebral Palsy (MACS)Time frame: "month" 12
  14. Change from baseline Pediatric Evaluation of Disability Inventory (PEDI)Time frame: Baseline
  15. Change from baseline Pediatric Evaluation of Disability Inventory (PEDI)Time frame: "month" 6
  16. Change from baseline Pediatric Evaluation of Disability Inventory (PEDI)Time frame: "month" 12
  17. Change from baseline Modified Ashworth scaleTime frame: Baseline
  18. Change from baseline Modified Ashworth scaleTime frame: "month" 1
  19. Change from baseline Modified Ashworth scaleTime frame: "month" 3
  20. Change from baseline Modified Ashworth scaleTime frame: "month" 6
  21. Change from baseline Modified Ashworth scaleTime frame: "month" 12

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Tehran University of Medical Sciences , Growth and Development Research Center- Children's Medical Center

    Tehran, Iran

  • Tehran University of Medical Sciences Chidren's Medical Center Radiology Department

    Tehran, Iran

  • Tehran University of Medical Sciences, Department of Pediatric Neurology , Children's Medical Center

    Tehran, Iran

  • ROYAN Stem Cell Technology Co

    Tehran, Iran

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.